U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939971) titled 'A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML' on Nov. 02.

Brief Summary: The goal of this interventional study is to learn if TBS-2025 is safe to administer to participants with relapsed/refractory (r/r) Acute Myeloid Leukemia (AML). The main questions it aims to answer are:

* What medical problems do adult participants have when taking TBS-2025?

* What does the body do from the time TBS-2025 enters the body until it is completely gone?

* What is the best dose of TBS-2025 to give to participants?

* Does TBS-2025 work to treat r/r AML?

Participants will:

* Take TBS-2025 every 2 weeks

* Visit the clinic ...